Arkolith/Insider Trading/LENZ/Form 4

Schimmelpennink Evert B.

President, CEO and Secretary, DirectorLENZ Therapeutics, Inc. (LENZ) · full profile →Form 4 · filed Mar 25, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
0 non-derivative · 4 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 21, 2024Grant(A)316K—$0316K
Mar 21, 2024Grant(A)83K—$083K
Mar 21, 2024Grant(A)387K—$0387K
Mar 21, 2024Grant(A)475K—$0475K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001815776-24-000020) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for LENZ Therapeutics, Inc.

Build

Ask your agent about LENZ insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001815776-24-000020"
Ask your agent
Use Arkolith to summarize insider buying and selling at LENZ Therapeutics, Inc.
over the last 90 days and cite the filings.